The Cold Open
Selank is the peptide biohackers reach for when they want benzo-style calm without the fog, the dependency, or the morning-after haze. The pitch writes itself: an anxiolytic you spray into your nose, approved as a medicine in Russia, used at doses measured in drops. The underlying science is more interesting than the marketing. This month: what Selank actually does, what the Russian trials show, and whether "gentler benzo" holds up.
Peptide of the Month: Selank
What it is. Selank is a seven-amino-acid synthetic peptide engineered from a natural immune peptide called tuftsin. It was developed in the late 1990s by Russian researchers and officially registered as a medicine in Russia in 2009, sold as a 0.15% intranasal drop. The intranasal route isn't a biohacker shortcut. It's the approved format, chosen because the nose delivers peptide to brain faster and more reliably than injection for a molecule this small.
What it's supposedly for. Anxiety, stress, mental fatigue, and a mild cognitive lift. Marketing framing: a non-sedating, non-addictive alternative to benzodiazepines like Xanax or Valium.
The evidence as of today. A 2008 Russian clinical trial compared Selank against the benzodiazepine medazepam in 62 patients with generalized anxiety disorder. Finding: similar anti-anxiety efficacy, with the added advantage that Selank did not produce the sedation or cognitive dulling typical of benzos. A second 2008 study found it shifted immune-cytokine balance in anxious patients, suggesting a real neuro-immune effect. Mechanistic studies since have shown Selank modulates the GABA system through gene expression changes, not direct receptor binding.
One thing to know: the geography problem. Almost all Selank evidence comes from Russian clinical programs. Large Phase III trials in Western populations do not exist.
Selank looks like a benzo on the outcome. It doesn't look like a benzo under the hood.
The catch. Selank is not FDA-approved. Every vial you buy in the US comes from a research-chemical vendor. Quality, concentration, and even the actual peptide identity vary widely between sellers. Beyond supply, the deeper issue is that the Russian clinical literature, while real, has not been independently replicated in large Western trials. Selank is a plausible and well-studied peptide by Russian standards. It is not a well-studied peptide by FDA standards.
Myth Check: "Selank is a safe, non-addictive benzo"
This is the line you'll hear on every biohacker podcast. It's half true, and the half that isn't matters.
Here's the accurate part. Selank works on the GABA system, which is the same system benzos target. In the head-to-head Russian trial, it produced comparable anxiety reduction. No dependence signal has been reported in the available literature. So far, so good.
Here's what the pitch glosses over. Selank does not bind GABA receptors directly. It changes the expression of genes that regulate GABA signaling, which is a fundamentally different mechanism. Calling it a "benzo" is a category error. It's a nudge to your GABA system, not an override of it. The effect profile is real but milder, which is why nobody in Russia treats acute panic attacks with Selank.
The rule: If you want benzo-strength relief, Selank isn't it. If you want something in the same general neighborhood with a cleaner side-effect profile and thinner evidence, that's what Selank actually is.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.